Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 20, 2021 - Issue 3
Submit an article Journal homepage
3,758
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance

Tomohiro Itoa Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6456-2825View further author information
ORCID Icon,
Yusuke Naitoa Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-8033-6708View further author information
ORCID Icon,
Naoki Shimmotoa Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanView further author information
,
Kaori Ochiaib PMS Center, Real World Evidence Business Headquarters, EPS Corporation, Tokyo, JapanView further author information
,
Naoyuki Hayashia Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanView further author information
&
Tomoo Okamuraa Medicine Division, Nippon Boehringer Ingelheim Co., Ltd, Tokyo, JapanView further author information
Pages 363-372 | Received 13 Nov 2020, Accepted 01 Dec 2020, Published online: 27 Dec 2020

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Nobuya Inagaki, Takaaki Nishimoto, Yoichi Nishiya & Daisuke Nitta. (2023) Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study. Expert Opinion on Drug Safety 22:2, pages 153-163.
Read now
Ali A. Rizvi, Ales Linhart, Michal Vrablik, Evangelos Liberopoulos & Manfredi Rizzo. (2022) Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opinion on Drug Safety 21:3, pages 291-293.
Read now
Keizo Kanasaki, Shen Qu, Fumiko Yamamoto, Cornelia Schepers, Rafael Sani Simões, Daisuke Yabe & Linong Ji. (2022) Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials. Expert Opinion on Drug Safety 21:3, pages 425-434.
Read now

Articles from other publishers (2)

. (2021) Multiple drugs. Reactions Weekly 1865:1, pages 289-289.
Crossref
Jaehyun Bae, Kee‐Ho Song, Jong Suk Park, Jae Hyuk Lee, In‐Kyung Jeong, Hyun Jin Kim, Young‐Hyo Lim, Jae‐Hyoung Cho, Sung Hee Choi, Yoon‐Sok Chung & Eun Seok Kang. (2021) Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes: A postmarketing surveillance study. Diabetes, Obesity and Metabolism 23:5, pages 1208-1212.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.